Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:52:03 UTC |
---|
HMDB ID | HMDB0015603 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Ximelagatran |
---|
Description | Ximelagatran, also known as exanta or H 376-95, belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. There was also a numerically higher mortality against warfarin. Ximelagatran is a drug which is used for the treatment of acute deep vein thrombosis. Ximelagatran was expected to replace warfarin and sometimes aspirin and heparin in many therapeutic settings, including deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation such as stroke. Ximelagatran is a very strong basic compound (based on its pKa). In humans, ximelagatran is involved in ximelagatran action pathway. Subsequent analysis of Phase 2 clinical study data using extreme value modelling (see Extreme value theory) showed that the elevated liver enzyme levels observed in Phase 3 clinical studies could have been predicted; if this had been known at the time, it might have affected decisions on future development of the compound. The efficacy of ximelagatran for these indications had been well documented, except for non valvular atrial fibrillation. A disadvantage recognised early was the absence of an antidote in case acute bleeding develops, while warfarin can be antagonised by prothrombin complex concentrate and/or vitamin K and heparin by protamine sulfate. Ximelagatran, a direct thrombin inhibitor, was the first member of this class that can be taken orally. It is taken orally twice daily, and rapidly absorbed by the small intestine. |
---|
Structure | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1 InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1 |
---|
Synonyms | Value | Source |
---|
Ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(n'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate | ChEBI | Exanta | ChEBI | Exarta | ChEBI | H 376-95 | ChEBI | H 376/95 | ChEBI | H 37695 | ChEBI | Ximelagatran (oxime form) | ChEBI | Ximelagatranum | ChEBI | Ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(n'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetic acid | Generator | XI-melagatran | HMDB | Glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester | HMDB | Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester | HMDB |
|
---|
Chemical Formula | C24H35N5O5 |
---|
Average Molecular Weight | 473.5652 |
---|
Monoisotopic Molecular Weight | 473.263819255 |
---|
IUPAC Name | ethyl 2-{[(1R)-1-cyclohexyl-2-[(2S)-2-[({4-[(Z)-N'-hydroxycarbamimidoyl]phenyl}methyl)carbamoyl]azetidin-1-yl]-2-oxoethyl]amino}acetate |
---|
Traditional Name | ximelagatran |
---|
CAS Registry Number | 192939-46-1 |
---|
SMILES | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1 |
---|
InChI Identifier | InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1 |
---|
InChI Key | ZXIBCJHYVWYIKI-PZJWPPBQSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Dipeptides |
---|
Alternative Parents | |
---|
Substituents | - Alpha-dipeptide
- Alpha-amino acid ester
- Alpha-amino acid amide
- Alpha-amino acid or derivatives
- Monocyclic benzene moiety
- Benzenoid
- Amidoxime
- Tertiary carboxylic acid amide
- Amino acid or derivatives
- Azetidine
- Carboxamide group
- Secondary carboxylic acid amide
- Carboxylic acid ester
- Amidine
- Azacycle
- Organoheterocyclic compound
- Secondary amine
- Secondary aliphatic amine
- Monocarboxylic acid or derivatives
- Carbonyl group
- Organic oxygen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic nitrogen compound
- Amine
- Organic oxide
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.084 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.68 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 10.5383 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.93 minutes | 32390414 | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 233.4 seconds | 40023050 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1316.0 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 167.5 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 162.0 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 165.8 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 97.6 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 317.0 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 354.4 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 961.6 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 805.2 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 351.4 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 970.5 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 215.7 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 279.4 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 317.0 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 490.2 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 133.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Ximelagatran,1TMS,isomer #1 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)C1CCCCC1 | 4145.6 | Semi standard non polar | 33892256 | Ximelagatran,1TMS,isomer #1 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)C1CCCCC1 | 3708.9 | Standard non polar | 33892256 | Ximelagatran,1TMS,isomer #1 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)C1CCCCC1 | 6234.4 | Standard polar | 33892256 | Ximelagatran,1TMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(N)=N/O)C=C1)C1CCCCC1)[Si](C)(C)C | 4030.1 | Semi standard non polar | 33892256 | Ximelagatran,1TMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(N)=N/O)C=C1)C1CCCCC1)[Si](C)(C)C | 3567.9 | Standard non polar | 33892256 | Ximelagatran,1TMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(N)=N/O)C=C1)C1CCCCC1)[Si](C)(C)C | 6625.6 | Standard polar | 33892256 | Ximelagatran,1TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C)C1CCCCC1 | 3971.1 | Semi standard non polar | 33892256 | Ximelagatran,1TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C)C1CCCCC1 | 3587.0 | Standard non polar | 33892256 | Ximelagatran,1TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C)C1CCCCC1 | 6521.3 | Standard polar | 33892256 | Ximelagatran,2TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C | 4043.1 | Semi standard non polar | 33892256 | Ximelagatran,2TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C | 3632.1 | Standard non polar | 33892256 | Ximelagatran,2TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C | 5875.9 | Standard polar | 33892256 | Ximelagatran,2TMS,isomer #2 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1 | 4006.0 | Semi standard non polar | 33892256 | Ximelagatran,2TMS,isomer #2 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1 | 3673.9 | Standard non polar | 33892256 | Ximelagatran,2TMS,isomer #2 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1 | 5737.4 | Standard polar | 33892256 | Ximelagatran,2TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)C1CCCCC1 | 4072.8 | Semi standard non polar | 33892256 | Ximelagatran,2TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)C1CCCCC1 | 3777.5 | Standard non polar | 33892256 | Ximelagatran,2TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)C1CCCCC1 | 5736.6 | Standard polar | 33892256 | Ximelagatran,2TMS,isomer #4 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 3917.8 | Semi standard non polar | 33892256 | Ximelagatran,2TMS,isomer #4 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 3544.6 | Standard non polar | 33892256 | Ximelagatran,2TMS,isomer #4 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 6289.1 | Standard polar | 33892256 | Ximelagatran,3TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 3958.9 | Semi standard non polar | 33892256 | Ximelagatran,3TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 3627.3 | Standard non polar | 33892256 | Ximelagatran,3TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 5356.6 | Standard polar | 33892256 | Ximelagatran,3TMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C | 4006.9 | Semi standard non polar | 33892256 | Ximelagatran,3TMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C | 3705.1 | Standard non polar | 33892256 | Ximelagatran,3TMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C | 5361.4 | Standard polar | 33892256 | Ximelagatran,3TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1 | 3952.7 | Semi standard non polar | 33892256 | Ximelagatran,3TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1 | 3751.7 | Standard non polar | 33892256 | Ximelagatran,3TMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1 | 5236.8 | Standard polar | 33892256 | Ximelagatran,4TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 3936.5 | Semi standard non polar | 33892256 | Ximelagatran,4TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 3694.9 | Standard non polar | 33892256 | Ximelagatran,4TMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C)[Si](C)(C)C)C=C1)[Si](C)(C)C)C1CCCCC1)[Si](C)(C)C | 4910.1 | Standard polar | 33892256 | Ximelagatran,1TBDMS,isomer #1 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1 | 4343.6 | Semi standard non polar | 33892256 | Ximelagatran,1TBDMS,isomer #1 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1 | 3879.4 | Standard non polar | 33892256 | Ximelagatran,1TBDMS,isomer #1 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1 | 6112.3 | Standard polar | 33892256 | Ximelagatran,1TBDMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(N)=N/O)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 4288.7 | Semi standard non polar | 33892256 | Ximelagatran,1TBDMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(N)=N/O)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 3743.7 | Standard non polar | 33892256 | Ximelagatran,1TBDMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(N)=N/O)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 6578.7 | Standard polar | 33892256 | Ximelagatran,1TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 4217.2 | Semi standard non polar | 33892256 | Ximelagatran,1TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 3760.7 | Standard non polar | 33892256 | Ximelagatran,1TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 6495.0 | Standard polar | 33892256 | Ximelagatran,2TBDMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 4481.2 | Semi standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 3969.5 | Standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 5739.3 | Standard polar | 33892256 | Ximelagatran,2TBDMS,isomer #2 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 4416.5 | Semi standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #2 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 4010.7 | Standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #2 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 5620.4 | Standard polar | 33892256 | Ximelagatran,2TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1 | 4500.3 | Semi standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1 | 4085.8 | Standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1 | 5590.7 | Standard polar | 33892256 | Ximelagatran,2TBDMS,isomer #4 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1)[Si](C)(C)C(C)(C)C | 4387.0 | Semi standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #4 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1)[Si](C)(C)C(C)(C)C | 3879.3 | Standard non polar | 33892256 | Ximelagatran,2TBDMS,isomer #4 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(N)=N/O)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1)[Si](C)(C)C(C)(C)C | 6218.6 | Standard polar | 33892256 | Ximelagatran,3TBDMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1)[Si](C)(C)C(C)(C)C | 4565.0 | Semi standard non polar | 33892256 | Ximelagatran,3TBDMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1)[Si](C)(C)C(C)(C)C | 4093.3 | Standard non polar | 33892256 | Ximelagatran,3TBDMS,isomer #1 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1)[Si](C)(C)C(C)(C)C | 5342.5 | Standard polar | 33892256 | Ximelagatran,3TBDMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 4628.3 | Semi standard non polar | 33892256 | Ximelagatran,3TBDMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 4150.1 | Standard non polar | 33892256 | Ximelagatran,3TBDMS,isomer #2 | CCOC(=O)CN([C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)C1CCCCC1)[Si](C)(C)C(C)(C)C | 5286.1 | Standard polar | 33892256 | Ximelagatran,3TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 4522.3 | Semi standard non polar | 33892256 | Ximelagatran,3TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 4197.4 | Standard non polar | 33892256 | Ximelagatran,3TBDMS,isomer #3 | CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)N(CC1=CC=C(/C(=N/O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)[Si](C)(C)C(C)(C)C)C1CCCCC1 | 5192.2 | Standard polar | 33892256 |
|
---|
General References | - Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S: A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003 Jan;1(1):41-7. [PubMed:12871538 ]
- Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr: Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349(18):1703-12. [PubMed:14585938 ]
- Weitz JI: New anticoagulants for treatment of venous thromboembolism. Circulation. 2004 Aug 31;110(9 Suppl 1):I19-26. [PubMed:15339877 ]
- Bergqvist D, Solhaug JH, Holmdahl L, Eriksson UG, Andersson M, Boberg B, Ogren M: Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery. Clin Drug Investig. 2004;24(3):127-36. [PubMed:17516699 ]
- Koscielny J, Kiesewetter H, Jorg I, Harenberg J: Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis. Clin Appl Thromb Hemost. 2007 Jul;13(3):299-307. [PubMed:17636192 ]
|
---|